Accuracy of Self-Reported Disability in Patients with Parkinsonism
Arch Neurol 46:955-959, Brown,R.G.,et al, 1989
The 5 Pillars in Tourette Syndrome Deep Brain Stimulation Patient Selection
Neurol 96:664-676, Martino, D.,et al, 2021
Suicide and Suicide Attempts after Subthalamic Nucleus Stimulation in Parkinson Disease
Neurol 93:e97-e105, Giannini, G.,et al, 2019
Treatment of Tics in People with Tourette Syndrome and Chronic Tic Disorders
Neurol 92:896-906, Pringsheim, T.,et al, 2019
National Randomized Controlled Trial of Virtual House Calls for Parkinson Disease
Neurol 89:1152-1161,1103, Beck, C.A.,et al, 2017
Diagnosis and Management of Dementia with Lewy Bodies
Neurol 89:88-100, McKeith, I.G.,et al, 2017
A 55-year-old Man with Rapidly Progressive Dementia and Parkinsonism
Neurol 89:e182-e187, Tabuas-Pereira, M.,et al, 2017
Efficacy and Safety of Cholinesterase Inhibitors and Memantine in Cognitive Impairment in Parkinsons Disease, Parkinsons Disease Dementia, and Dementia with Lewy Bodies: Systematic Review with Meta-Analysis and Trial Sequential Analysis
JNNP 86:135-143, Wang, H.F.,et al, 2015
The Acquired Metabolic Disorders of the Nervous System, Carbon Monoxide Poisoning
Adams & Victors Principles of Neurology Chp 40, pg 1138, Ropper, A.H.,et al, 2014
Systematic Review: Efficacy and Safety of Medical Marijuana in Selected Neurologic Disorders
Neurol 82:1556-1563, Koppel, B.S.,et al, 2014
Palliative Care and Neurology
Neurol 83:561-567, Boersma, I.,et al, 2014
Deep-Brain Stimulation for Parkinsons Disease
NEJM 367:1529-1538, Okon, M.S., 2012
Deep Brain Stimulation for Parkinson Disease: An Expert Consensus and Review of Key Issues
Arch Neurol 68:165-171, Bronstein,J.M.,et al, 2011
Prolactinomas
NEJM 362:1219-1226, Klibanski,A., 2010
Quality of Anticoagulation Control in Atrial Fibrillation
Lancet 376:935-937, Lane,D.A. &Lip,G.Y.H., 2010
Tourettes Syndrome
NEJM 363:2332-2338, Kurlan,R., 2010
Potentially Preventable Strokes in High-Risk Patients with Atrial Fibrillation Who Are Not Adequately Anticoagulated
Stroke 40:235-240,5, Gladstone,D.J.,et al, 2009
Second Consensus Statement on the Diagnosis of Multiple System Atrophy
Neurol 71:670-676, Gilman,S.,et al., 2008
Attempted and Completed Suicides After Subthalamic Nucleus Stimulation for Parkinsons Disease
JNNP 79:952-954, Soulas,T.,et al., 2008
Treatment Options in the Modern Management of Parkinson Disease
Arch Neurol 64:1083-1088, Schapira,A.H.V., 2007
Valvular Heart Disease and the Use of Dopamine Agonists for Parkinsons Disease
NEJM 356:39-46, Zanettini,R.,et al, 2007
The Pull Test:A History
Mov Disord 21:894-899, Hunt,A.L.,et al, 2006
Practice Parameter: Neuroprotective Strategies and Alternative Therapies for Parkinson Disease (An Evidence-Based Review)
Neurol 66:976-982, Suchowersky,O.,et al, 2006
Suicide After Deep Brain Stimulation of the Internal Globus Pallidus for Dystonia
Neurol 66:142-143, Foncke,E.M.J.,et al, 2006
Practice Parameter: Evaluation and Treatment of Depression, Psychosis, and Dementia in Parkinson Disease (An Evidence-Based Review)
Neurol 66:996-1002, Miyasaki,J.M.,et al, 2006
Practice Parameter: Treatment of Parkinson Disease with Motor Fluctuations and Dyskinesia (An Evidence-Based Review)
Neurol 66:983-995, Pahwa,R.,et al, 2006
Practice Parameter: Diagnosis and Prognosis of New Onset Parkinson Disease (An Evidence-Based Review)
Neurol 66:968-975, Suchowersky,O.,et al, 2006
Diagnosis and Initial Management of Parkinsons Disease
NEJM 353:1021-1027, Nutt,J.G.&Wooten,G.F., 2005
Suicide After Successful Deep Brain Stimulation for Movement Disorders
Neurol 63:2170-2172, Burkhard,P.R.,et al, 2004
Stalevo for Parkinson's Disease
The Medical Letter 46:39, , 2004
Restless Legs Syndrome
NEJM 348:2103-2109, Earley,C.J., 2003
Effect on Mood of Subthalamic DBS for Parkinson's Disease
Neurol 59:1427-1429, Berney,A.,et al, 2002
Practice Parameter: Initiation of Treatment for Parkinson's Disease: An Evidence-based Review
Neurol 58:11-17, Miyasaki,J.M.,et al, 2002
Deep Brain Stimulation in the Treatment of Parkinson's Disease,A Cost-Effectiveness Analysis
Neurol 57:663-671, Tomaszewski,K.J.&Holloway,R.G., 2001
Comtan (Entacapone) The Treatment of Parkinson's Disease, Questions & Answers
APDA Ed Suppl #15, Watts,R.L., 2001
Complications of Gamma Knife Surgery for Parkinson Disease
Arch Neurol 58:1995-2002,1970, Okun,M.S.,et al, 2001
Use of Placebo Surgery in Controlled Trials of a Cellular-Based Therapy for Parkinson's Disease
NEJM 341:988-992, Freeman,T.B.,et al, 1999
Clinicopath Conf:Multisystem Neurodegenerative Disease with Dementia Pugilistica
NEJM 340:1269-1277, Case 12-1999, 1999
Practice Styles of US Compared to UK Neurologists
Neurol 50:1661-1668, Vickrey,B.G.,et al, 1998
Neurological Sequelae of Cyanide Intoxication-The Patterns of Clinical MRI & Pet Findings
Ann Neurol 38:825-828, Rosenow,F.,et al, 1995
Practice Parameters:Initial Therapy of Parkinson's Disease
Report of the Quality Standards Subcommittee of AAN, Neurol 43:1296-12971993., , 1993
Suicide and Patients with Neurologic Diseases, Methodologic Problems
Arch Neurol 49:1296-1303, Stenager,E.N.&Stenager,E., 1992
Neurological and Neuropsychiatric Spectrum of Wilson's Disease:A Prospective Study of 45 Cases
J Neurol 238:281-287, Oder,W.,et al, 1991
A Pure Parkinsonian Syndrome Following Acute Carbon Monoxide Intoxication
Arch Neurol 39:302-304, Klawans,H.L.,et al, 1982
Self-Grasping:A Focal Neurological Sign
Ann Neurol 12:575-577, Ropper,A.H., 1982
Wait Time to See a Neurologist After Referral Among Medicare Participants
Neurol 104:e210217, Lin,C.C.,et al, 2025
Palliative and End-of-Life Care in Stroke:A Scientific Statement from the American Heart Association
Stroke 56;e75-e86, Creutzfeldt,C.J.,et al, 2025
FUTURE-AI: International Consensus Guideline for Trustworthy and Deployable Artificial Intelligence in Healthcare
BMJ 388:e081554, Lekadir,K.,et al, 2025
Methamphetamine-Induced Basal Ganglia Toxicity Presenting as Parkinsonism
Neurol 104:e213365, Yi,M.Y.,et al, 2025